Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,471
Recruiting: 1,282
Ph III recruiting: 129
Growth YoY: +2.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,643)

clinicaltrialsPublishedShowing 651–700 of 1,574 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06993675	Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)(ROTATE)	recruiting	Phase 2	50	Noffar BarOTHER	1	May 13, 2026	clinicaltrials
NCT07259070	Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma	recruiting	Phase 1 / Phase 2	20	Institute of Hematology & Blood Diseases Hospital, China